For example, the Galectin-1 inhibitor showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1 (Gheysen et al., 2021), and the Galectin-1 inhibitor had been used to treat B-cell precursor acute lymphoblastic leukemia (Paz et al., 2018) and head and neck squamous cell carcinomas (Koonce et al., 2017). Here, LGALS1 is linked to head and neck squamous cell carcinoma.